Call for application


Swiss Bridge is a private foundation associated with the Swiss Cancer League, the Swiss Cancer Research foundation and the Union for International Cancer Control (UICC), and supports high-quality cancer research in Europe. This year, on the occasion of the 20th anniversary of the Swiss Bridge foundation, funding is provided for investigators who have made outstanding contributions in the field of rare cancers* (preference will be given to young investigators**).

Investigators from academic and cancer research institutions in Europe are invited to submit a note of intent for a new cancer research project before 30 April 2016.

The proposals will be evaluated by an international scientific jury. 6 – 8 investigators will be shortlisted and invited to submit a detailed research application by end of July 2016. Upon peer review and recommendation from the scientific jury, up to 4 projects will receive funding amounting to a total support of 1 000 000 Swiss francs.

The winners will be invited to an awards ceremony to be held on 26 October 2016.

The entire note of intent including attachments may not exceed 6 pages (3 000 words) and must include:

-   the title of the project

-   the name, address and affiliation of the principal investigator

-   the domain of research (basic, clinical, translational, other – please specify)

-   the principal investigator’s short curriculum vitae

-   a support letter from the employer

-   the name(s), address(es) and affiliation(s) of the co-applicant(s)

-   the project period (max. 3 years)

-   the amount of financial support requested (max. 350 000 Swiss francs)

-   a summary of the project (1–2 pages)

-   a list of up to 12 publications by the principal investigator (please provide the following information: h-index, total number of publications and total sum of citations) and

-   a statement regarding the relevance and potential contribution of the project to control of rare cancers (1–2 pages)


Please ensure the information provided in your proposal is complete and adheres to the above guidelines before submitting to

Office of the Scientific Board of the Swiss Bridge Foundation
c/o Swiss Cancer League
PO Box 8219
CH-3001 Berne

* Rare tumours are identified as those having an incidence rate less than 6/100,000/year. See also

** Please note that the term young investigator refers to early stage researchers (e.g. research associates, junior group leaders, assistant professors or scientists establishing their own research group) holding a PhD or MD and having done at least one post-doc.